Catalyst Wire Dossier Catalyst Wire Dossier

GB263T

· Genor Biopharma Co., Ltd.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for GB263T, covering 2022-08-05 to 2022-08-05. Get the full timeline:

Most recent: Clinical Trial Update: A Safety, Tolerability, PK and Preliminary Activity Study of GB263T in Advanced NSCLC and Other Solid Tumor [Phase 1, Phase 2]

See pricing